With Ozempic going generic globally… what happens to the “research use only” peptide market?

I was reading a recent piece from The New York Times about semaglutide (Ozempic/Wegovy) going generic in countries like India, China, and Canada… and it got me thinking about something I haven’t really seen discussed much here.

We might be heading toward a weird split: Outside the U.S. → cheaper, legit generic GLP-1s everywhere Inside the U.S. → still locked behind patents, high prices, limited access That gap is where things get interesting. Because right now, a big part of the “research use only” peptide space (especially GLP-1s like semaglutide, tirzepatide, etc.) exists because of that access problem.

So what happens if:

Generics become widely available globally Prices drop dramatically

Supply increases from legit manufacturers

A few possibilities I keep thinking about:

1. The gray/research market shrinks (at least for GLP-1s)

If people can get pharma-grade semaglutide cheaply and legally (even if not in the U.S.), demand for “research” versions might drop—especially among more risk-averse users.

2. Or… it actually expands On the flip side, lower global prices could:

Increase overall awareness and demand Normalize peptide use

Push more people down the rabbit hole (which is usually how people end up exploring research peptides in the first place)

3. Price pressure hits research vendors If legit generics are selling for a fraction of current U.S. prices, it’s hard to imagine the research market not adjusting.

Margins compress, and the market probably splits into:

Low-cost/high-volume suppliers

“Premium” research brands emphasizing purity, testing, etc.

4. Regulatory pressure increases As these compounds become more mainstream globally, I wouldn’t be surprised if:

U.S. regulators tighten enforcement on research sales

Platforms (TikTok, Reddit, payment processors) get stricter

More scrutiny hits anything even adjacent to human use

5. Shift toward newer / less accessible peptides If semaglutide becomes commoditized globally, the research market might just move:

Retatrutide MOTS-c SS-31 Other newer or less-regulated compounds

Basically, wherever access is still limited.

Big picture: It feels like GLP-1s might follow a similar path to what we’ve seen in other spaces:

Start as expensive, tightly controlled

Move to global generics

Then become widely accessible (with parallel gray markets evolving alongside)

Curious what you guys think: Does this kill part of the research peptide market… or fuel it?

Do people stick with cheaper global generics, or keep using research sources?

And longer term — does this legitimize peptides overall, or bring more crackdowns?